JPMorgan Chase Bank, National Association London EC4Y 0JP EnglandBase Call Option Transaction • August 9th, 2010 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between JPMorgan Chase Bank, National Association, London Branch (“Dealer”) and Gilead Sciences, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for this Transaction.
JPMorgan Chase Bank, National Association London EC4Y 0JP EnglandWarrant Agreement • August 9th, 2010 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Gilead Sciences, Inc. (“Company”) to JPMorgan Chase Bank, National Association, London Branch (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for this Transaction.
Goldman, Sachs & Co. New York, New York 10282-2198 Telephone No.: (212) 902-1000Warrant Agreement • August 9th, 2010 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Gilead Sciences, Inc. (“Company”) to Goldman, Sachs & Co. (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for this Transaction.
EMTRICITABINE MANUFACTURING SUPPLY AGREEMENT AMENDMENT NO. 1Emtricitabine Manufacturing Supply Agreement • August 9th, 2010 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT (the “Amendment No. 1”) to the Emtricitabine Manufacturing Supply Agreement is entered into as of April 30, 2010, by and between Evonik Degussa GmbH (formerly known as Degussa AG), a German limited liability company (“Evonik”) and Gilead Sciences Limited, an Irish limited company (“GSL”).
AGREEMENT AND PLAN OF MERGER dated as of June 23, 2010 By and Among GILEAD SCIENCES, INC., COUGAR MERGER SUB, INC., CGI PHARMACEUTICALS, INC. and SH REP, LLC, AS REPRESENTATIVEMerger Agreement • August 9th, 2010 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of June 23, 2010, by and among Gilead Sciences, Inc., a Delaware corporation (“Parent”), Cougar Merger Sub, Inc., a Delaware corporation (“AcquisitionCo”), CGI Pharmaceuticals, Inc., a Delaware corporation (the “Company”) (AcquisitionCo and the Company being hereinafter sometimes referred to as the “Constituent Corporations”), and SH Rep, LLC, a Connecticut Limited Liability Company, as representative of the Participants (as defined herein) (the “Representative”).
